Literature DB >> 24567085

Prostate cancer: The role of local therapy for metastatic prostate cancer.

Lorenzo Tosco1, Hendrik Van Poppel1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24567085     DOI： 10.1038/nrurol.2014.33

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

Review 1.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

2.  Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.

Authors:  Piet Ost; Karel Decaestecker; Bieke Lambert; Valérie Fonteyne; Louke Delrue; Nicolaas Lumen; Filip Ameye; Gert De Meerleer
Journal:  Prostate       Date:  2014-02       Impact factor: 4.104

3.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Authors:  Patrizio Rigatti; Nazareno Suardi; Alberto Briganti; Luigi F Da Pozzo; Manuela Tutolo; Luca Villa; Andrea Gallina; Umberto Capitanio; Firas Abdollah; Vincenzo Scattoni; Renzo Colombo; Massimo Freschi; Maria Picchio; Cristina Messa; Giorgio Guazzoni; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-08-03       Impact factor: 20.096

Review 4.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

5.  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Authors:  Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin
Journal:  Eur Urol       Date:  2012-08-10       Impact factor: 20.096

6.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.

Authors:  Stephen H Culp; Paul F Schellhammer; Michael B Williams
Journal:  Eur Urol       Date:  2013-11-20       Impact factor: 20.096

7.  Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Authors:  James L Mohler; Andrew J Armstrong; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas Farrington; Celestia S Higano; Eric Mark Horwitz; Philip W Kantoff; Mark H Kawachi; Michael Kuettel; Richard J Lee; Gary R MacVicar; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Stan Rosenfeld; Sandy Srinivas; Seth A Strope; Jonathan Tward; Przemyslaw Twardowski; Patrick C Walsh; Maria Ho; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2012-09       Impact factor: 11.908

8.  Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer.

Authors:  Jutta Engel; Patrick J Bastian; Helmut Baur; Volker Beer; Christian Chaussy; Juergen E Gschwend; Ralph Oberneder; Karl H Rothenberger; Christian G Stief; Dieter Hölzel
Journal:  Eur Urol       Date:  2010-01-20       Impact factor: 20.096

9.  Complications and functional results of surgery for locally advanced prostate cancer.

Authors:  S G Joniau; A A Van Baelen; C Y Hsu; H P Van Poppel
Journal:  Adv Urol       Date:  2012-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.